Wuhan Institute of Virology, Chinese Academy of Sciences: Oral nucleoside prodrug VV261 can effectively inhibit Chikungunya virus replication

The team of Professor Xiao Gengfu and Professor Zhang Lei from the Wuhan Institute of Virology, Chinese Academy of Sciences, in collaboration with Professor Shen Jingshan from the Shanghai Institute of Materia Medica, published a research progress article titled “Investigation of a clinical trial drug VV261 as a potent antiviral candidate against Chikungunya virus” in the journal Signal Transduction and Targeted Therapy. The study identified an oral nucleoside prodrug, VV261, which has entered clinical research and can effectively inhibit the replication of the Chikungunya virus. VV261 has previously entered Phase I clinical trials for the treatment of Dengue virus infection. This research provides important support for expanding the potential indications of this candidate drug. The related experiments were completed at the National Biosafety Laboratory of the Chinese Academy of Sciences in Wuhan. (Wuhan Institute of Virology, Chinese Academy of Sciences)